COPENHAGEN—Novo Nordisk is in advanced talks to acquire assets to bolster its struggling biopharma business, its chief executive said on Oct. 14 after the drugmaker announced it had hired an AstraZeneca executive to head the unit.
Novo, best known for its diabetes drugs, has been looking for biopharma assets after losing out to French rival Sanofi in the chase for Belgian biotech company Ablynx in January.
